UBACT Principles of UFMylation-driven antibacterial defence
- Coordinator
- Universite De Geneve, Switzerland
- Runs
- 1 May 2027 to 30 April 2032
- Status
- Running
- EU funding
- €1.9m
- Total cost
- €2.3m
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101301321
What the project is doing
In the project's own words, from its summary on CORDIS.
Shigella is a Gram-negative bacterium that causes bacillary dysentery, killing around 200 thousand people each year and representing an urgent global threat due to rising antibiotic resistance. Beyond its medical relevance, Shigella has long been a paradigm in cellular microbiology, yielding landmark insights into host–pathogen interactions and illuminating fundamental mechanisms in cell biology. In my recent work, I discovered that UFMylation—a ubiquitin-like protein modification pathway with established roles in cell homeostasis—functions as a novel antibacterial defence mechanism.
UFMylation marks intracellular bacteria such as Shigella for elimination, in a process independent from canonical ubiquitylation and autophagy, thereby uncovering an unexpected and largely unexplored branch of host immunity. The proposed project will elucidate the fundamental mechanisms of antibacterial UFMylation, revealing novel molecular principles of host recognition of intracellular bacteria, downstream pathways driving microbial elimination, and sophisticated pathogen evasion strategies.
I will further investigate how these molecular events intersect, compete and ultimately impact UFMylation-mediated homeostasis at the cellular and tissue levels, repositioning this pathway at the interface between host defence and physiology. Through the integration of in vitro reconstitution systems, cellular assays and organoid models, and leveraging the powerful molecular toolkit of Shigella, this project is uniquely positioned to deliver breakthrough discoveries in the field of host-pathogen interactions and cell biology.
Advancing our fundamental understanding of UFMylation may inspire innovative therapeutic strategies against antimicrobial-resistant infections, while also informing pathological conditions associated with UFMylation, such as cancer, inflammation, and Alzheimer’s disease.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universite De Geneve | Geneve | Switzerland | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI